MediPharm Labs Corp. (MEDIF)
| Previous Close | 0.0612 |
| Open | 0.0600 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0600 - 0.0623 |
| 52 Week Range | 0.0400 - 0.0770 |
| Volume | |
| Avg. Volume | 113,783 |
| Market Cap | 25.006M |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
MediPharm Labs Sets Date to Report First Quarter 2024 Financial Results
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the period ended March 31, 2024, before markets open on Wednesday, May 15, 2024.
- CNW Group
MediPharm Labs Provides Conference Call Recording Details
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, has released and hosted a conference call regarding its full year and fourth quarter financial results for the period ended December 31, 2023.
- CNW Group
MediPharm Labs Reports Fourth Quarter and Full Year Results
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.
